Caris Life Sciences disclosed finalized results from the Achieve I study for its multi-cancer early detection test, Caris Detect, reporting sensitivity and specificity across stage I to stage IV cancers. The study enrolled 3,014 patients who were evaluable based on high-risk screening, symptomatic presentation, or imaging-detected masses. The reporting emphasizes stage-by-stage sensitivity, with specificity described for asymptomatic and benign/high-risk groups, and highlights performance differences by cancer type. Caris said its whole-genome sequencing-based approach uses molecular profiling data to identify early-stage signals with AI models trained on Caris’ database. Caris also noted expectations for adding additional technologies such as whole-transcriptome sequencing to strengthen overall performance. The finalized dataset moves the company from interim views to a complete, reported-out evaluation. For the MCED market, the release provides a concrete evidence update as companies race toward commercialization timelines and payer conversations, where specificity and clinical utility thresholds matter.